{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Hong G"],"funding":["Korea Health Technology R&D Project through the Korea Health Industry Development Institute, funded by the Ministry of Health & Welfare, Republic of Korea","Basic Science Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Science and Technology","Korea Health Technology R&amp;D Project through the Korea Health Industry Development Institute, funded by the Ministry of Health &amp; Welfare, Republic of Korea","Chungnam National University Hospital Research Fund"],"pagination":["159-171"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9889409"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["149(1)"],"pubmed_abstract":["<h4>Purpose</h4>Although increased plasma growth differentiation factor-15 (GDF15) levels have been reported in patients with various cancers, the predictive role of PD-1/PD-L1 inhibitors in advanced cancers remains unknown. This study aimed to investigate GDF15 levels as a predictive marker in advanced non-small cell lung cancer (NSCLC) treated with PD-1/PD-L1 inhibitors and analyze their association with immune cell populations.<h4>Methods</h4>This study included 87 patients with advanced NSCLC receiving anti-PD-1/PD-L1 inhibitors between March 2018 and May 2020. Blood samples were obtained immediately before and months after PD-1/PD-L1 inhibitor administration.<h4>Results</h4>The objective response rate (ORR) was significantly higher in the low GDF15 than in the high GDF15 group (39.2% vs. 15.3%, P = 0.013). The median progression-free survival (PFS) was significantly longer in the low GDF15 than in the high GDF15 group (13.2 [95% CI 7.6-18.9] vs. 7.2 [95% CI 4.8-9.6] months, P = 0.048). Moreover, plasma GDF15 levels negatively correlated with PD-1<sup>+</sup>/CD8<sup>+</sup> T cells (r = - 0.399, P = 0.003) and positively with PD-1<sup>+</sup>/Treg cells (r = 0.507, P < 0.001) and PD-1<sup>+</sup>Treg/CD4<sup>+</sup> T cells (r = 0.439, P < 0.001). The ORR was significantly higher in the group with decreased GDF15 from baseline than in the increased GDF15 group (37.2% vs. 10.0%, P = 0.026). The median PFS was significantly longer in the decreased GDF15 group (14.8 [95% CI 10.4-19.2] vs. 5.9 [95% CI 2.8-9.0] months, P = 0.002). Plasma GDF15 levels were associated with PD-1<sup>+</sup>CD8<sup>+</sup> T cells and PD-1<sup>+</sup> Treg cells.<h4>Conclusion</h4>Plasma GDF15 could be a potential biomarker for predicting the efficacy and survival benefit of immunotherapy in advanced NSCLC."],"journal":["Journal of cancer research and clinical oncology"],"pubmed_title":["Plasma GDF15 levels associated with circulating immune cells predict the efficacy of PD-1/PD-L1 inhibitor treatment and prognosis in patients with advanced non-small cell lung cancer."],"pmcid":["PMC9889409"],"funding_grant_id":["HR22C1734","NRF-2022R1C1C1007301","NRF-2021R1C1C1011183","2021"],"pubmed_authors":["Chung C","Lee JE","Kang DH","Sun P","Lee SI","Lee SE","Hong G","Kang YE","Park D","Kim N"],"additional_accession":[]},"is_claimable":false,"name":"Plasma GDF15 levels associated with circulating immune cells predict the efficacy of PD-1/PD-L1 inhibitor treatment and prognosis in patients with advanced non-small cell lung cancer.","description":"<h4>Purpose</h4>Although increased plasma growth differentiation factor-15 (GDF15) levels have been reported in patients with various cancers, the predictive role of PD-1/PD-L1 inhibitors in advanced cancers remains unknown. This study aimed to investigate GDF15 levels as a predictive marker in advanced non-small cell lung cancer (NSCLC) treated with PD-1/PD-L1 inhibitors and analyze their association with immune cell populations.<h4>Methods</h4>This study included 87 patients with advanced NSCLC receiving anti-PD-1/PD-L1 inhibitors between March 2018 and May 2020. Blood samples were obtained immediately before and months after PD-1/PD-L1 inhibitor administration.<h4>Results</h4>The objective response rate (ORR) was significantly higher in the low GDF15 than in the high GDF15 group (39.2% vs. 15.3%, P = 0.013). The median progression-free survival (PFS) was significantly longer in the low GDF15 than in the high GDF15 group (13.2 [95% CI 7.6-18.9] vs. 7.2 [95% CI 4.8-9.6] months, P = 0.048). Moreover, plasma GDF15 levels negatively correlated with PD-1<sup>+</sup>/CD8<sup>+</sup> T cells (r = - 0.399, P = 0.003) and positively with PD-1<sup>+</sup>/Treg cells (r = 0.507, P < 0.001) and PD-1<sup>+</sup>Treg/CD4<sup>+</sup> T cells (r = 0.439, P < 0.001). The ORR was significantly higher in the group with decreased GDF15 from baseline than in the increased GDF15 group (37.2% vs. 10.0%, P = 0.026). The median PFS was significantly longer in the decreased GDF15 group (14.8 [95% CI 10.4-19.2] vs. 5.9 [95% CI 2.8-9.0] months, P = 0.002). Plasma GDF15 levels were associated with PD-1<sup>+</sup>CD8<sup>+</sup> T cells and PD-1<sup>+</sup> Treg cells.<h4>Conclusion</h4>Plasma GDF15 could be a potential biomarker for predicting the efficacy and survival benefit of immunotherapy in advanced NSCLC.","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jan","modification":"2025-04-21T22:49:48.282Z","creation":"2025-04-05T18:52:42.686Z"},"accession":"S-EPMC9889409","cross_references":{"pubmed":["36472770"],"doi":["10.1007/s00432-022-04500-5"]}}